---
title: "Blog — Insights & Updates | QbD Group"
description: "Stay informed with the latest regulatory insights, industry news, and expert perspectives from QbD Group."
url: https://qbdgroup.com/en/blog
type: "Page"
language: en
publisher: "QbD Group"
citation: "QbD Group, \"Blog — Insights & Updates | QbD Group\", https://qbdgroup.com/en/blog"
---

[FeaturedQuality AssuranceRegulatory ToxicologyNovember 13, 2026Where Biological Evaluations Fall Short, and How to Close the GapsFive common gaps in medical device biological evaluations, from unjustified endpoints to weak chemical characterization, and how to close each one.Read article](https://qbdgroup.com/en/blog/biological-evaluation-gaps-how-to-close)

[Regulatory AffairsRegulatory ToxicologyNov 13, 2026Has Anything Changed Since Your Last Biological Evaluation? Questions Every Manufacturer Should AskISO 10993-1:2025 is out. Nine practical questions to check whether your medical device biological evaluation still holds, without unnecessary re-testing.Read more](https://qbdgroup.com/en/blog/biological-evaluation-iso-10993-1-questions)

[Quality AssuranceNov 4, 2026CAPA Backlog as a Quality Signal: From Triage to Lasting Inspection ReadinessLearn how to manage CAPA backlogs through risk-based triage, root cause analysis and effectiveness checks to strengthen GMP inspection readiness.Read more](https://qbdgroup.com/en/blog/capa-backlog-management-inspection-readiness)

[Regulatory AffairsNov 4, 2026Grouping and Worksharing Under the 2025 EU Variations Guidelines: A Practical ApproachLearn how to use grouping and worksharing under the 2025 EU Variations Guidelines to coordinate submissions and improve lifecycle planning.Read more](https://qbdgroup.com/en/blog/eu-variations-grouping-worksharing-guide)

[PharmacovigilanceNov 4, 2026Integrating EudraVigilance Data Into Signal Management: How to Choose the Right ApproachExplore three ways to integrate EudraVigilance data into signal management, from validation and evaluation to risk-based detection and monitoring.Read more](https://qbdgroup.com/en/blog/eudravigilance-signal-management-approaches)

[Regulatory AffairsQuality AssuranceOct 21, 2026Your App Just Became a Medical Device. Now What?Your app qualifies as a medical device. Learn what EU MDR means for clinical evidence, Agile development, ISO 13485, CE marking and ongoing compliance.Read more](https://qbdgroup.com/en/blog/app-medical-device-eu-mdr-requirements)

[Regulatory AffairsSoftware Solutions & ServicesQuality AssuranceOct 21, 2026Wellness App or Medical Device? Your Intended Purpose DecidesWhen does a wellness app become a medical device under the EU MDR? Explore intended purpose, software qualification, Rule 11 and common grey areas.Read more](https://qbdgroup.com/en/blog/wellness-app-or-medical-device-intended-purpose)

[Software Solutions & ServicesRegulatory AffairsOct 14, 2026Why Existing In-House Data Rarely Gets IVD Software Through IVDRDiscover why in-house data often falls short of IVDR clinical performance requirements for IVD software and how to choose the right study design.Read more](https://qbdgroup.com/en/blog/ivd-software-in-house-data-clinical-performance)

[Software Solutions & ServicesOct 14, 2026The Six Questions an Inspector Will Ask About Your AIIs your AI use inspection-ready? Explore six questions GMP inspectors may ask about AI governance, human oversight, model changes and validation.Read more](https://qbdgroup.com/en/blog/six-gmp-inspection-questions-ai-governance)

[ClinicalOct 14, 2026Six Mistakes That Can Impact Your HPV Assay ValidationDiscover six common HPV assay validation mistakes, from sample selection and cut-off optimisation to population differences and platform changes.Read more](https://qbdgroup.com/en/blog/hpv-assay-validation-mistakes)

[Software Solutions & ServicesRegulatory AffairsOct 14, 2026Bringing Your US-Authorised AI Diagnostic to Europe: What Transfers and What Doesn'tMoving an FDA-cleared AI diagnostic to Europe? Learn what evidence transfers, what IVDR requires and how a gap assessment can guide CE marking.Read more](https://qbdgroup.com/en/blog/fda-to-ivdr-ai-diagnostics-evidence-gap-assessment)

[ClinicalOct 14, 2026One Study, Two Markets: Designing HPV Clinical Performance Studies for IVDR and WHO PQCan one HPV clinical performance study support both IVDR and WHO Prequalification? Learn how to align requirements and avoid duplicate studies.Read more](https://qbdgroup.com/en/blog/hpv-clinical-performance-studies-ivdr-who-pq)

[ClinicalOct 14, 2026The Meijer Criteria Explained: Why They Matter for Your HPV AssayExplore the Meijer criteria for HPV assay validation, including clinical sensitivity, specificity, reproducibility and their role in IVDR and WHO PQ.Read more](https://qbdgroup.com/en/blog/meijer-criteria-hpv-assay-validation-ivdr-who-pq)

[Software Solutions & ServicesOct 14, 2026Six Ways LLMs Can Trip You Up in GMPDiscover six risks of using LLMs in GMP, from hallucinations and inconsistent outputs to data leakage, and how to manage them responsibly.Read more](https://qbdgroup.com/en/blog/llm-pitfalls-gmp-generative-ai-risks)

---

Source: https://qbdgroup.com/en/blog — © QbD Group. Quote freely with attribution and a link back.
